| SEMAGLUTIDE |
Wegovy® |
NOVO NORDISK PHARMACEUTICALS PTY. LIMITED |
Established atherosclerotic cardiovascular disease (eASCVD) with obesity |
Nov 2026 |
Pending PBAC outcome |
| SEMAGLUTIDE |
Wegovy® |
NOVO NORDISK PHARMACEUTICALS PTY. LIMITED |
Established cardiovascular disease (eCVD) with obesity |
Nov 2025 |
Recommended |
| SEMAGLUTIDE |
Ozempic® |
NOVO NORDISK PHARMACEUTICALS PTY. LIMITED |
Diabetes mellitus type 2 (T2DM) |
Nov 2024 |
Recommended |
| SEMAGLUTIDE |
Wegovy® |
Novo Nordisk Pharmaceuticals Pty. Limited |
Severe obesity |
Nov 2023 |
Not Recommended |
| SEMAGLUTIDE |
Wegovy® |
Novo Nordisk Pharmaceuticals Pty. Limited |
Obesity |
Mar 2022 |
Not Recommended |
| SEMAGLUTIDE |
Ozempic® |
Novo Nordisk Pharmaceuticals Pty. Ltd |
Type 2 diabetes mellitus (T2DM) |
Mar 2021 |
Recommended |
| SEMAGLUTIDE |
Ozempic® |
Novo Nordisk Pharmaceuticals Pty Ltd |
Type 2 diabetes mellitus (T2DM) |
Mar 2020 |
Recommended |
| SEMAGLUTIDE |
Ozempic® |
Novo Nordisk Pharmaceuticals Pty Ltd |
Type 2 diabetes mellitus (T2DM) |
Nov 2019 |
Recommended |